Skip to main content

Pixium Vision announces attendance at upcoming conferences

Pixium Vision announces attendance at upcoming conferencesParis, September 14th 2020 – 17.30 pm CET– Pixium Vision (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announces that management will attend and present at the following upcoming conferences:      ·HC Wainwright & Co. 22ndAnnual Global Investment Conference: Virtual Conference
            Mixed physical (New York) and digital event, September 14th to 16th
            Pixium Vision to present on Wednesday 16th September at 3:30pm ET (9.30 p.m. CET)
             
      ·LSX’s Healthtech Leaders: Virtual Partnering and Investment
            Digital event, September 15th to 18th
            Pixium Vision to present on Tuesday 15th September at 9:00am BST (10.00 a.m. CET) in Company Showcase session
             
      ·Lyon- les Rendez-vous mensuels de Lyon Pôle Bourse
            Physical event, October 6th from 5.00pm to 7.00pm CET in Lyon (France)
            Lloyd Diamond to present the Company at 6pm and answer questions in a Q&A session
             
      ·MedTech Strategist Investment & Partnering Summit 2020
            Digital event, October 15th to November 20th on-demand
            One-to-one meetings
             
      ·NEXT French Healthcare 2020
            Virtual business roadshow, October 13th to 23rd
            One-to-one meetings
             
      ·Dry AMD Therapeutic Development Summit
            Digital event, October 28th to 29th
            Pixium Vision to present on Thursday 29th October at 11:00am-11-30am ET (5.00 p.m.-5.30 p.m. CET)
             
             
Additional events
             
High Net Worth event in Zurich – Lunch – October 2nd High Net Worth event in Monaco – Lunch – October 12thHigh Net Worth event in Luxembourg – Lunch – October 29thVirtual Key Opinion Leader (KOL) event – October 30th   at 10:30 am ET (4.30 p.m. CET) (details will be available on Pixium Vision website)             ContactsPixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.For more information:  http://www.pixium-vision.com/frFollow us on @PixiumVision;  www.facebook.com/pixiumvision              www.linkedin.com/company/pixium-vision Pixium Vision is listed on Euronext Growth Paris. Euronext ticker: ALPIX - ISIN: FR0011950641 Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles. Pixium Vision is included in the Euronext GROWTH ALLSHARE index

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.